Probucol in Hypercholesterolemia A Multiple Open Study

Abstract

The effect of Probucol on serum lipids and lipoprotein was studied in 51 patients with primary hypercholesterolemia in multiple open study. After 1 month of placebo period the patients received 4×250mg of Probucol per day for 4 months. Total and VLDL+LDL cholesterol were significantly reduced with Probucol (23-24% and 22-23 respectively). The concentration of serum triglyceride was not significantly altered. The concentration of HDL cholesterol was reduced under Probucol treatment (25-31%). The Total chol-HDL-chol ratio during Probucol was increased (22%). In general, the subjective and objective tolerance of the drug was excellent.